Recombinant PE Anti-CBL antibody [YE323] - C-terminal (ab224917)
![Flow Cytometry (Intracellular) - PE Anti-CBL antibody [YE323] - C-terminal (ab224917)](https://www.abcam.com/ps/products/224/ab224917/Images/ab224917-323750-anti-cbl-antibody-ye323-c-terminal-phycoerythrin-flow-cytometry.jpg "Flow Cytometry (Intracellular) - PE Anti-CBL antibody [YE323] - C-terminal (ab224917)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- PE Rabbit monoclonal [YE323] to CBL - C-terminal
- Suitable for: Flow Cyt (Intra)
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
Related conjugates and formulations
Overview
-
Product name
PE Anti-CBL antibody [YE323] - C-terminal
See all CBL primary antibodies -
Description
PE Rabbit monoclonal [YE323] to CBL - C-terminal -
Host species
Rabbit -
Conjugation
PE. Ex: 488nm, Em: 575nm -
Tested applications
Suitable for: Flow Cyt (Intra)more details -
Species reactivity
Reacts with: Human
Predicted to work with: Chicken
-
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Epitope
ab224917 reacts with an epitope located in the C terminal region of CBL. -
Positive control
- Flow Cyt (intra): Jurkat cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 1% BSA, PBS -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
YE323 -
Isotype
IgG -
Research areas
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Co-activators/co-repressors
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab224917 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt (Intra) |
1/5000.
The cellular localisation of this product has been verified in ICC/IF. |
| Notes |
|---|
|
Flow Cyt (Intra)
1/5000. The cellular localisation of this product has been verified in ICC/IF. |
Target
-
Function
Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. -
Pathway
Protein modification; protein ubiquitination. -
Involvement in disease
Defects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. -
Sequence similarities
Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain. -
Domain
The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain. -
Post-translational
modificationsPhosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 374038 Chicken
- Entrez Gene: 867 Human
- Omim: 165360 Human
- SwissProt: P22681 Human
- Unigene: 504096 Human
-
Alternative names
- 4732447J05Rik antibody
- C CBL antibody
- Cas Br M (murine) ecotropic retroviral transforming sequence antibody
see all
Images
-
Flow Cytometry (Intracellular) - PE Anti-CBL antibody [YE323] - C-terminal (ab224917)
Overlay histogram showing Jurkat (Human T cell leukemia cell line from peripheral blood) cells stained with ab224917 (red line).
The cells were fixed with 4% formaldehyde (10 min) and then permeabilized with 0.1% PBS-Triton X-100 for 15 min. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab224917, 1/5000 dilution) for 30 min at 22°C.
Isotype control antibody (black line) was Rabbit IgG (monoclonal) Phycoerythrin (ab209478) used at the same concentration and conditions as the primary antibody. Unlabeled sample (blue line) was also used as a control.
Acquisition of >5,000 events were collected using a 50 mW Yellow/Green laser (561nm) and 586/15 bandpass filter.
This antibody gave a positive signal in Jurkat cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Triton X-100 for 15 min used under the same conditions.
-
![PE Anti-CBL antibody [YE323] - C-terminal (ab224917)](https://www.abcam.com/ps/products/224/ab224917/Images/ab224917-3-benefits-of-recombinant-antibodies.png)
PE Anti-CBL antibody [YE323] - C-terminal (ab224917)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab224917 has not yet been referenced specifically in any publications.